The coronavirus disease 2019 (COVID-19) pandemic has resulted in \>14 million confirmed cases and 611,823 deaths worldwide as of July 20, 2020 (Worldometer, [*https://www.worldometers.info/coronavirus*](https://www.worldometers.info/coronavirus){#intref0010}). Clinically, COVID-19 has markedly varied presentations, with most patients being asymptomatic or having mild symptoms.[@bib1] A small group of patients, however, develop severe acute respiratory syndrome, which is associated with high mortality.[@bib2] ^,^ [@bib3] Demographic features and certain comorbidities, including male sex, age \>65 years, African American race, hypertension, obesity, and diabetes, are associated with adverse outcome.[@bib1] ^,^ [@bib3] However, many COVID-19 patients without those features also have developed severe lung injury or acute respiratory distress syndrome (ARDS).[@bib3] According to a report from New York, 14% hospitalized COVID-19 patients presented with a severe case requiring intensive care due to significant hypoxia.[@bib3] However, the susceptibility of developing severe lung injury is not fully understood.

SARS-CoV-2 and the RAS {#sec1}
======================

Like severe acute respiratory syndrome--associated coronavirus (SARS-CoV), which caused an outbreak in 2002, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also uses angiotensin-converting enzyme (ACE) 2 as a binding receptor to enter the cell.[@bib4] ^,^ [@bib5] The binding and the subsequent cell entry of SARS-CoV lead to exhaustion of ACE2 and the reduced expression of cellular ACE2.[@bib6], [@bib7], [@bib8] These observations are mirrored in SARS-CoV-2 infection and have renewed interest in studying the modulation of renin-angiotensin system (RAS) in COVID-19.[@bib6] Organ distribution of ACE2, binding of ACE2 with SARS-CoV and SARS-CoV-2, and subsequent modulation of RAS are discussed in detail in other reviews.[@bib9], [@bib10], [@bib11]

ACE and ACE2 are the two key modulators of RAS.[@bib12] ACE converts angiotensin I to angiotensin II (ATII) and degrades the bioactive bradykinin.[@bib13] ACE2 converts ATII to AT 1 to 7.[@bib14] The interaction between ACE and ACE2 appears to be reciprocal, with one down-regulated while the other is up-regulated[@bib15] as the balance between the two is critical in maintaining the physiological homeostasis of RAS. In conditions where tissue or plasma ACE activity is increased or ACE2 expression is decreased, such as in SARS-CoV-2 infection, ATII level becomes unopposed, which may contribute to acute lung injury through various mechanisms, including the following. It increases vascular permeability and causes vasoconstriction.[@bib14] Moreover, it induces the apoptosis of endothelial cells and of alveolar epithelial cells.[@bib16] ^,^ [@bib17] In addition, it promotes fibrosis.[@bib18] Last, it boosts the proinflammatory mediators, including IL-6 and IL-8.[@bib19] The regulation of RAS is illustrated schematically in [Figure 1](#fig1){ref-type="fig"} .Figure 1The diagram illustrates the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the main metabolic pathways driven by angiotensin-converting enzyme (ACE) and ACE2 in the renin-angiotensin system, proposed mechanisms of ACE *DD* genotype in the severe lung injury of coronavirus disease 2019, and the potential impact of ACE *DD* genotype in the high-risk population. The potential therapeutic targets for ACE inhibitors (ACEIs) and angiotensin (AT) 1 receptor blockers (ARBs) are also shown.

Angiotensin II and Acute Lung Injury {#sec2}
====================================

Experimental and clinical studies support that the imbalance between ACE and ACE2 and subsequent increased ATII play a significant pathologic role in acute lung injury. In animal model with influenza, the reduction of ACE2 expression appears to be associated with severe lung injury.[@bib20] Similarly, binding of SARS-CoV to mouse ACE2 *in vivo* causes reduced ACE2 expression and greater acute lung injury.[@bib8] In a separate mouse model where the lung injury is induced by high-volume ventilation, there appears to be an increased lung injury related to the overproduction of lung ATII.[@bib21] In humans, serum ATII level is markedly elevated in patients with ARDS and sepsis,[@bib22] ^,^ [@bib23] where the microvascular reoxygenation rate and plasma ATII level are inversely associated.[@bib23] In a small cohort of COVID-19 patients, plasma ATII levels are markedly elevated compared with healthy controls and are linearly correlated with viral load and the severity of lung injury,[@bib24] suggesting a systemic RAS imbalance as a result of ACE2 down-regulation from SARS-CoV-2 infection.

ACE Gene Polymorphism and Acute Lung Injury {#sec3}
===========================================

ACE gene polymorphism is characterized by the insertion (*I*) or deletion (*D*) of a 287-bp Alu repeat sequence in intron 16 of the ACE gene. The insertion/deletion (*I*/*D*) polymorphism has been associated with circulating and tissue ACE levels and determines nearly half of the serum ACE level variability in general population,[@bib25] where the *D* allele is associated with higher ACE activity.[@bib26] Mean ACE activity levels in *DD* carriers were approximately twice that in *II* genotype individuals.[@bib25] Therefore, we propose a hypothesis that ACE gene polymorphism may play an important role in patients with COVID-19 who are susceptible to develop severe lung injury or ARDS.

There is an abundance of evidence supporting the relationship of ACE *I/D* polymorphism and clinical outcome of ARDS. In one study, the 28-day mortality rates are significantly different between the three ACE *I/D* genotypes (42%, 65%, and 75% for *II*, *ID*, and *DD*, respectively). Patients with the *II* genotype have a significantly better survival than those with the non-*II* genotypes.[@bib27] In another study, the *DD* genotype frequency is higher in patients with ARDS and is significantly associated with mortality.[@bib28] In a prospective study of ARDS, increased mortality of more than fivefold is found in patients with a homozygous *DD* genotype compared with the *II* genotype.[@bib29]

The relation between ACE gene polymorphism and the disease severity has been investigated in SARS, which caused an outbreak in 2002 that affected \>8000 individuals and resulted in 774 deaths worldwide (World Health Organization: cumulative number of reported probable cases of SARS), with mixed results. The frequency of the ACE gene *D* allele is significantly higher in the hypoxemic group than in the nonhypoxemic group in a small study.[@bib30] However, a later study failed to show a significant association of ACE polymorphism with the pulmonary disease severity in the SARS patients.[@bib31] To date, there have been few published studies examining the relation of ACE gene polymorphism with acute lung injury of COVID-19. Nevertheless, it is plausible that the severity of acute lung injury of COVID-19 is influenced to some extent by the genotypes of ACE *I/D* polymorphism. Likely, genetic susceptibility of severe lung injury from SARS-CoV-2 infection is complex and mediated by multiple genes. A recent large genome-wide association study has reported a novel susceptibility locus associated with ABO blood group in COVID-19 patients with severe lung injury.[@bib32] Further exploration of genetic susceptibility of severe SARS-CoV-2 infection is warranted.

ACE Gene Polymorphism and the COVID-19 Pandemic in Various Populations {#sec4}
======================================================================

The racial difference of ACE gene polymorphism is well established. For example, in the United States, African Americans are known to have the highest frequency of the *D* allele (89%) when compared with Indians (69%) and whites (69%).[@bib33] In Europe, populations in Italy, Spain, and France have a high frequency of *D* allele up to 82% to 87%.[@bib34] In contrast, in Asia, the Eastern Asian populations, such as Chinese, Korean, Taiwanese, and Japanese, have a high frequency of ACE gene *II* allele, which is reportedly higher than the European populations (33% to 51% versus 13% to 27%).[@bib35] It is apparent that the racial variance of ACE *I/D* genotype seems to coincide with the differences of outcomes where the populations with high frequency of *D* alleles seem to experience higher fatality. For example, African Americans seem to have the disproportionately high fatality rate in the United States.[@bib36] ^,^ [@bib37] Similarly, patients from Italy, Spain, and France also experience high fatality in Europe. Conversely, the low frequency of ACE *D/D* and high frequency of *II* genotype seen in Asian populations seem to be associated with relatively low fatality of COVID-19 in those nations ([*https://www.worldometers.info/coronavirus/\#countries*](https://www.worldometers.info/coronavirus/#countries){#intref0015}). Although socioeconomic and environmental conditions may play a role, they do not fully explain the severity of acute lung injury in COVID-19. A Scottish study concluded from the observation of influenza that socioeconomic factors do not fully explain ethnic variations in hospitalization for lower respiratory tract infections.[@bib38]

Potential Benefit of ACE Inhibitors and ATII Receptor Blockers in COVID-19 {#sec5}
==========================================================================

Animal models have demonstrated promising evidence of an attenuated lung injury by the ACE inhibitors and/or ACE receptor blockers (ARBs) from SARS-CoV infection[@bib8] and from ventilation overdrive.[@bib8] ^,^ [@bib21] Several retrospective studies have been published recently on the impact of ACE inhibitors and ARBs in patients with COVID-19. The use of ACE inhibitors and ARBs was associated with lower risk of all-cause mortality among hospitalized patients with COVID-19.[@bib39] Furthermore, the prior use of ACE inhibitors/ARBs was not associated with increased mortality or severe disease in patients with COVID-19.[@bib40] In addition, the use of ACE inhibitors in SARS-CoV-2 positive patients with hypertension is associated with nearly 40% lower risk of hospitalization.[@bib41] Although limited by the observational nature, these studies offer important support to the ongoing randomized controlled studies where new evidence will be emerging soon for the efficacy of ACE inhibitors and ARBs as treatment for COVID-19 (NCT04367883, NCT04366050, NCT04312009, and NCT04311177; [*https://clinicaltrials.gov*](https://clinicaltrials.gov){#intref0020}). Although speculative, we anticipate a greater efficacy for those with *DD* genotype because it is associated with higher ACE level than other genotypes should ACE gene polymorphism be tested.

Summary {#sec6}
=======

ACE2 is a binding receptor for SARS-CoV-2 to enter the cell. The down-regulation of ACE2 as a result of SARS-CoV-2 infection is likely the important mechanism of acute lung injury or ARDS related to COVID-19 because of the resultant imbalance between ACE and ACE2 and the overproduction of ATII. The ACE gene polymorphism, which accounts for the differences of the ACE level in general population, may be responsible for the susceptibility to severe lung injury in COVID-19 patients. The absence of ACE *D/D* genotype in patients with COVID-19 may be protective against developing severe lung injury. Conversely, the presence of ACE *D/D* allele may be favorable for ACE inhibitors and ARB therapy. In our view, it is highly desirable to test ACE gene polymorphism for COVID-19 patients in the ongoing clinical trials with ACE inhibitors and ARBs. The association, if confirmed, may help to individualize the treatment and to optimize the outcome based on the genotype.
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